(2009). 18F FDG PET/CT EVALUATION OF PATIENTS WITH CERVICAL CARCINOMA IAGARU, A.(1), EL-MAGHRABY, T. (2), QUON, A. (1), GAMBHIR, S.S. (1) and MCDOUGALL, I.R. (1) (1) Nuclear Medicine Division, Stanford University Hospital, California, USA and (2) Nuclear Medicine Unit, Cairo University Hospitals, Cairo, Egypt,. test, 1(1), 63-75. doi: 10.21608/egyjnm.2009.3303
. "18F FDG PET/CT EVALUATION OF PATIENTS WITH CERVICAL CARCINOMA IAGARU, A.(1), EL-MAGHRABY, T. (2), QUON, A. (1), GAMBHIR, S.S. (1) and MCDOUGALL, I.R. (1) (1) Nuclear Medicine Division, Stanford University Hospital, California, USA and (2) Nuclear Medicine Unit, Cairo University Hospitals, Cairo, Egypt,". test, 1, 1, 2009, 63-75. doi: 10.21608/egyjnm.2009.3303
(2009). '18F FDG PET/CT EVALUATION OF PATIENTS WITH CERVICAL CARCINOMA IAGARU, A.(1), EL-MAGHRABY, T. (2), QUON, A. (1), GAMBHIR, S.S. (1) and MCDOUGALL, I.R. (1) (1) Nuclear Medicine Division, Stanford University Hospital, California, USA and (2) Nuclear Medicine Unit, Cairo University Hospitals, Cairo, Egypt,', test, 1(1), pp. 63-75. doi: 10.21608/egyjnm.2009.3303
18F FDG PET/CT EVALUATION OF PATIENTS WITH CERVICAL CARCINOMA IAGARU, A.(1), EL-MAGHRABY, T. (2), QUON, A. (1), GAMBHIR, S.S. (1) and MCDOUGALL, I.R. (1) (1) Nuclear Medicine Division, Stanford University Hospital, California, USA and (2) Nuclear Medicine Unit, Cairo University Hospitals, Cairo, Egypt,. test, 2009; 1(1): 63-75. doi: 10.21608/egyjnm.2009.3303

18F FDG PET/CT EVALUATION OF PATIENTS WITH CERVICAL CARCINOMA IAGARU, A.(1), EL-MAGHRABY, T. (2), QUON, A. (1), GAMBHIR, S.S. (1) and MCDOUGALL, I.R. (1) (1) Nuclear Medicine Division, Stanford University Hospital, California, USA and (2) Nuclear Medicine Unit, Cairo University Hospitals, Cairo, Egypt,

Egyptian Journal Nuclear Medicine
Article 5, Volume 1, Issue 1, March 2009, Pages 63-75    PDF (257.61 K)
Document Type: Original Article
DOI: 10.21608/egyjnm.2009.3303
Abstract
Objectives: 18F FDG PET/CT is becoming widely available as a powerful imaging modality, combining the ability
to detect active metabolic processes and their morphologic features in a single exam. The role of 18F FDG PET was
studied in a variety of cancers, including cervical carcinoma, however, not PET/CT was not used in the majority of
the published studies. Therefore, the airs of this work is to show role of PET/CT in the management of patients with cervical carcinoma.
Methods: This is a retrospective study of 30 women with cervical carcinoma, age is reneged from 28-87 years old (average: 49.6 ± 15.7). wholebody PET/CT was done in Stanford university hospital during the period from Jan 1st, 2003 to Aug 31st, 2006. Reinterpretation of the imaging studies for accuracy and data analysis from medical records were performed.
Sensitivity and specificity were calculated with pathology results (76% of the patients) or clinical follow-up (24% of the cases). Confidence interval (CI) estimations were performed using the Wilson score method.
Results: All patients had the study requested for disease re-staging. A total of 42 scans were performed: 18 pts had 1 scan and 12 pts had 2 scans. The administered doses of 18F FDG ranged 10.5 - 20.0 mCi (average: 15.3 ± 2.31).
PET/CT was 92.8% sensitive (95% CI: 66.4-99.9) and 92.8% specific (95% CI: 76.3-99.1) for detection of the primary
lesion and 95.6% (95% CI: 77.3-99.9) sensitive and 94.7% specific (95% CI: 73.5-99.9) for metastases detection. The
SUVmax ranged 5.3-28.2 for the primary lesions (average: 12.5±6.96) and 2.8-22.9 for the metastases (average: 7.72±4.46). This difference was statistically significant (P value: 0.0058). 
Conclusion: This study confirms the good results of 18F FDG PET/CT for identification of residual/recurrent cervical cancer, as well as for distant metastases localization. FDG PET/CT should be an integral part in evaluation of patients with high risk cervical cancer, prior to selection of the most appropriate therapy. 
Statistics
Article View: 192
PDF Download: 264